Koelker, M;
Labban, M;
Frego, N;
Meyer, CP;
Salomon, G;
Lipsitz, SR;
Withington, J;
... Cole, AP; + view all
(2023)
Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry.
World Journal of Urology
, 41
(5)
pp. 1309-1315.
10.1007/s00345-023-04354-7.
![[thumbnail of nihms-1920070.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
nihms-1920070.pdf - Accepted Version Access restricted to UCL open access staff until 18 March 2025. Download (338kB) |
Abstract
PURPOSE: To describe the national-level patterns of care for local ablative therapy among men with PCa and identify patient- and hospital-level factors associated with the receipt of these techniques. METHODS: We retrospectively interrogated the National Cancer Database (NCDB) for men with clinically localized PCa between 2010 and 2017. The main outcome was receipt of local tumor ablation with either cryo- or laser-ablation, and “other method of local tumor destruction including high-intensity focused ultrasound (HIFU)”. Patient level, hospital level, and demographic variables were collected. Mixed effect logistic regression models were fitted to identify separately patient- and hospital-level predictors of receipt of local ablative therapy. RESULTS: Overall, 11,278 patients received ablative therapy, of whom 78.8% had cryotherapy, 15.6% had laser, and 5.7% had another method including HIFU. At the patient level, men with intermediate-risk PCa were more likely to be treated with local ablative therapy (OR 1.05; 95% CI 1.00–1.11; p = 0.05), as were men with Charlson Comorbidity Index > 1 (OR 1.36; 95% CI 1.29–1.43; p < 0.01), men between 71 and 80 years (OR 3.70; 95% CI 3.43–3.99; p < 0.01), men with Medicare insurance (OR 1.38; 95% 1.31–1.46; p < 0.01), and an income < $47,999 (OR 1.16; 95% CI 1.06–1.21; p < 0.01). At the hospital-level, local ablative therapy was less likely to be performed in academic/research facilities (OR 0.45; 95% CI 0.32–0.64; p < 0.01). CONCLUSIONS: Local ablative therapy for PCa treatment is more commonly offered among older and comorbid patients. Future studies should investigate the uptake of these technologies in non-hospital-based settings and in light of recent changes in insurance coverage.
Archive Staff Only
 |
View Item |
